Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evenamide - Newron Pharmaceuticals

Drug Profile

Evenamide - Newron Pharmaceuticals

Alternative Names: NW-3509; NW-3509A

Latest Information Update: 18 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Newron Pharmaceuticals
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 11 Aug 2020 Evenamide - Newron Pharmaceuticals is available for licensing as of 11 Aug 2020. https://www.newron.com/
  • 11 Aug 2020 Newron Pharmaceuticals plans a phase III trials for Schizophrenia (Adjunctive treatment) (PO) in second quarter of 2021
  • 03 Jul 2020 Newron Pharmaceuticals initiates enrolment in the phase II trial for Schizophrenia (Adjunctive treatment) in USA and India (PO) (NCT04461119)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top